Welcome to our dedicated page for TRANSLATE BIO news (Ticker: TBIO), a resource for investors and traders seeking the latest updates and insights on TRANSLATE BIO stock.
Telesis Bio Inc. (TBIO) generates news centered on automated DNA and mRNA synthesis technologies, strategic collaborations and corporate developments. The company describes itself as a public company based in San Diego, California, focused on enabling scientists to produce high-fidelity DNA and mRNA directly in their own laboratories using its Gibson SOLA Enzymatic Synthesis platform and BioXp benchtop systems.
News coverage for Telesis Bio often highlights progress and adoption of the Gibson SOLA™ platform, which the company presents as a non-toxic, high-fidelity and scalable enzymatic DNA and mRNA synthesis technology. Announcements have included licensing agreements, such as the deployment of Gibson SOLA at Regeneron Pharmaceuticals’ R&D core facilities, and collaborations that integrate Gibson SOLA with third-party automation platforms to support on-premises biofoundry capabilities.
Investors and researchers following TBIO can expect updates on partnerships and collaborations, including the company’s strategic research collaboration and license agreement with Pfizer related to enzymatic DNA synthesis for potential mRNA-based vaccines and other biopharma products. Additional news may cover agreements with automation and life sciences companies to co-develop and market integrated solutions for high-throughput nucleic acid synthesis.
Corporate and capital markets developments also appear in Telesis Bio’s news flow. Examples include restructuring activities, strategic focus on Gibson SOLA and BioXp mRNA solutions, reverse stock split actions, and the company’s decision to voluntarily delist from The Nasdaq Global Select Market and pursue quotation on over-the-counter markets. For anyone tracking TBIO, the news stream provides context on how the company is positioning its synthesis platforms, managing its cost structure and engaging with partners in synthetic biology and drug discovery workflows.
Translate Bio (Nasdaq: TBIO) announced the granting of non-qualified stock options for 238,200 shares to fifteen new employees, effective June 7, 2021. This initiative is part of the 2021 Inducement Stock Incentive Plan and aims to attract talent. The options have an exercise price of $19.12, aligned with the stock's closing price on the grant date. Vested over four years, these options require continued employment for vesting. Translate Bio focuses on mRNA therapeutics, especially for pulmonary diseases like cystic fibrosis and is collaborating on mRNA vaccines with Sanofi Pasteur.
Translate Bio (Nasdaq: TBIO) has reached a significant milestone in its collaboration with Sanofi Pasteur, receiving a $50 million payment for the successful manufacturing and delivery of a clinical drug product for an influenza mRNA vaccine. This payment precedes the anticipated start of a Phase 1 clinical trial to evaluate the vaccine candidate. The ongoing collaboration aims to develop mRNA vaccines for multiple infectious diseases, leveraging the expertise of both companies. This achievement marks progress in the mRNA vaccine platform development, enhancing Translate Bio's position in the market.
Translate Bio (Nasdaq: TBIO) announced its participation in two upcoming investor conferences. The CEO, Ronald Renaud, will engage in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 10:30 a.m. ET, and at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 3:50 p.m. ET. A live webcast of these sessions will be available on the company's website, with replays accessible for 30 days post-event. Translate Bio focuses on mRNA therapeutics, particularly for pulmonary diseases, and collaborates with Sanofi Pasteur on mRNA vaccines.
Translate Bio (Nasdaq: TBIO) announced promising preclinical results for a new mRNA-based therapeutic aimed at treating primary ciliary dyskinesia (PCD) due to DNAI1 mutations. The study showed that the delivery of mRNA to the lungs can enhance DNAI1 expression, potentially restoring mucociliary clearance, a crucial mechanism impaired in PCD. The company plans to further advance this candidate into IND-enabling studies in the second half of 2021, addressing a significant unmet need as no approved therapies currently exist for PCD.
Translate Bio (TBIO) continues to progress in developing mRNA therapeutics, reporting a net income of $26.5 million for Q1 2021. Significant advancements include the initiation of a COVID-19 vaccine trial (MRT5500) in partnership with Sanofi Pasteur, with interim results expected in Q3 2021. The company also published promising preclinical results for MRT5500. Additionally, the ongoing Phase 1/2 trial for MRT5005 in cystic fibrosis suggests safety and tolerability. Translate Bio has a strong cash position of $654.8 million, funding operations through 2023.
Translate Bio (Nasdaq: TBIO) announced on May 3, 2021, the grant of non-qualified stock options for 51,200 shares to six new employees as part of its 2021 Inducement Stock Incentive Plan. The options have an exercise price of $23.03 per share, equal to the stock's closing price on the grant date. They vest over four years, with 25% vesting on May 3, 2022, and the remainder in monthly installments. Translate Bio is focused on developing mRNA therapeutics, particularly for pulmonary diseases like cystic fibrosis.
Translate Bio (Nasdaq: TBIO) announced that CEO Ronald Renaud will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021, at 10:30 a.m. EST. A live webcast will be available on the company’s website, and a replay will be archived for 30 days post-event.
Translate Bio focuses on developing mRNA therapeutics for treating diseases like cystic fibrosis and also collaborates with Sanofi Pasteur on mRNA vaccines.
Translate Bio (Nasdaq: TBIO) announced the grant of 201,800 non-qualified stock options to Brendan Smith, its new CFO, on April 19, 2021. This grant is part of the 2021 Inducement Stock Incentive Plan and aligns with Nasdaq Listing Rule 5635(c)(4). The exercise price is set at $19.23 per share, equal to the closing stock price on that date. The options have a 10-year term with a four-year vesting schedule. Translate Bio focuses on developing mRNA therapeutics for various diseases, including a candidate for cystic fibrosis currently in clinical trials.
Translate Bio (Nasdaq: TBIO) announced key leadership appointments on April 19, 2021, aimed at advancing its strategic plan, TBIO 2025. Brendan Smith was appointed Chief Financial Officer, bringing over 20 years of experience in biopharma. Greg Troiano became Chief Manufacturing Officer, enhancing the company's manufacturing capabilities, while Jim Sullivan was named Senior Vice President for Pulmonary Discovery, focusing on mRNA therapeutics for pulmonary diseases. The appointments align with the company's goal of enhancing its R&D investments and advancing multiple drug programs into clinical stages.
Translate Bio (Nasdaq: TBIO) published preclinical results for its COVID-19 vaccine candidate MRT5500, demonstrating strong immune responses and protective efficacy against SARS-CoV-2 in studies involving multiple species. The vaccine, developed with Sanofi Pasteur, showed that MRT5500 induces neutralizing antibodies and protection against infection in hamster models. A Phase 1/2 clinical trial started in March 2021, with results expected in Q3 2021. The findings support the potential of MRT5500 as an effective vaccination option against COVID-19.